Phio Pharmaceuticals Corp. Common Stock (PHIO) is a publicly traded Healthcare sector company. As of May 21, 2026, PHIO trades at $1.06 with a market cap of $12.55M and a P/E ratio of -0.74. PHIO moved +0.00% today. Year to date, PHIO is -7.69%; over the trailing twelve months it is -40.98%. Its 52-week range spans $0.81 to $9.79. Analyst consensus is buy with an average price target of $14.00. Rallies surfaces PHIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Phio to Host May 19 Fireside Chat as PH-762 Delivers 65% Response Rate: Phio’s Phase 1b trial of PH-762 in skin cancers treated 22 patients across five dose cohorts with no dose-limiting toxicities and achieved a 65% pathological response rate overall and 85% at the highest dose. The company plans FDA engagement in Q2 2026 and maintains cash runway into H1 2027.
| Metric | Value |
|---|---|
| Price | $1.06 |
| Market Cap | $12.55M |
| P/E Ratio | -0.74 |
| EPS | $-1.45 |
| Dividend Yield | 0.00% |
| 52-Week High | $9.79 |
| 52-Week Low | $0.81 |
| Volume | 21 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-8.70M |
| Gross Margin | 0.00% |
1 analysts cover PHIO: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.00.